CTLA4 and pneumonitis: The incidence of ICI-associated pneumonitis in anti-PD-1/PD-L1 monotherapy and anti-CTLA-4/anti-PD-1 combination therapy is reported to be 2.5–5% and 7–10% [64], respectively.